ArticleProstate international2025
Treatment outcomes with radium-223 in patients with metastatic castration-resistant prostate cancer with bone metastasis in real-world practice: a multiinstitutional study.
Article in Prostate international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radium-223 (Ra-223) treatment is used to extend the overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. However, the optimal timing for its administration remains ambiguous. Hence, this study aimed to determine the optimal timing for Ra-223 administration. Materials and methods: We retrospectively included Japanese men with mCRPC with bone metastases who were treated with Ra-223. The primary endpoint was OS from Ra-223 treatment. Secondary endpoints included the maximum reduction in alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and prostate-specific antigen (PSA) levels and the incidence of adverse events following Ra-223 treatment. The exploratory endpoint was the association between clinical parameters and OS. Results: Overall, 100 men with mCRPC with bone metastasis treated with Ra-223 wereenrolled. The median OS from the Ra-223 treatment was 38.6 months. Post Ra-223 treatment, ALP, LDH, and PSA levels decreased in 78.6%, 56.1%, and 44.9% of patients, respectively. Grade ≥3 anemia occurred in three (4.1%) patients. The median OS of patients with ≥10 months from diagnosis to developing mCRPC (52.4 months, Conclusions: Ra-223 treatment is safe and effective for mCRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.